MDHHS Michigan Department of Health & Human Services

Medical Services Administration

BULLETIN MSA

Bulletin Number: MSA 21-22

Distribution: Practitioners, Outpatient Hospitals, Clinical Laboratories, Federally Qualified Health Centers, Local Health Departments, Rural Health Clinics, Tribal Health Centers

Issued: July 1, 2021

Subject: Multi-Gene Panel Laboratory Tests

Effective: August 1, 2021

Programs Affected: Medicaid, Healthy Michigan Plan, MIChild, Children's Special Health Care Services (CSHCS), Maternity Outpatient Medical Services (MOMS)

This policy applies to Medicaid Fee-for-Service (FFS). Medicaid Health Plans (MHPs) and Integrated Care Organizations (ICOs) must provide the full range of covered services described in this policy at a minimum and may choose to provide services over and above those specified. For beneficiaries enrolled in an MHP or ICO, the provider must check with the beneficiary's health plan for applicable coding, billing, and authorization instructions.

The purpose of this bulletin is to standardize the billing and coding of next generation sequencing (NGS) multi-gene panel laboratory tests across laboratory providers. These changes align Michigan Medicaid with the Centers for Medicare & Medicaid Services (CMS) claim submission requirements when multiple genes are tested.

Medicaid defines multi-gene panels as any assay that simultaneously tests for more than one gene associated with a condition or symptom. The term "gene" when used throughout this policy will be used to indicate a gene, region of a gene, and/or variant(s) of a gene.

Genes assayed on the same date of service will be considered assayed in parallel if the result of one assay does not affect the decision to complete the assay on another gene, and the genes are being tested for the same indication. Effective for dates of service on and after August 1, 2021, if a laboratory assays multiple genes simultaneously in parallel, then those genes will be considered part of the same panel. As a panel constitutes a single procedural service, one procedure code must be submitted for the panel. The laboratory should not report multiple individual procedure codes describing the gene component test results.

If a procedure code is available for the multi-gene panel test, this procedure code should be utilized. If no procedure code accurately describes the panel performed, an unlisted molecular pathology or unlisted molecular multi-analyte assay with algorithmic analysis procedure code (as applicable) may be used. When an unlisted procedure code is reported, providers should include the name of the panel test in box 21 of the Genetic and Molecular Laboratory Test Authorization Request form (MSA-2081). The test name should also be reported in the Procedure Code Comment field in the MDHHS Community Health Automated Medicaid Processing System (CHAMPS) authorization form. Required use of a panel or unlisted molecular procedure code by Medicaid does not imply the code or laboratory test is a Medicaid covered service.

Genes assayed on the same date of service will be considered assayed serially when the results of one or more gene analyses determines whether additional analyses are reasonable and necessary. When genes are serially assayed, the laboratory should submit claims with the genes reported individually.

Manual Maintenance

Retain this bulletin until the information is incorporated into the MDHHS Medicaid Provider Manual.

Questions

Any questions regarding this bulletin should be directed to Provider Inquiry, Department of Health and Human Services, P.O. Box 30731, Lansing, Michigan 48909-8231, or e-mailed to ProviderSupport@michigan.gov. When you submit an e-mail, be sure to include your name, affiliation, NPI number, and phone number so you may be contacted if necessary. Typical Providers may phone toll-free 1-800-292-2550. Atypical Providers may phone toll-free 1-800-979-4662.

An electronic version of this document is available at www.michigan.gov/medicaidproviders >> Policy, Letters & Forms.

Approved



Kate Massey, Director
Medical Services Administration